{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:02:07Z","timestamp":1762506127504},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11,1]]},"DOI":"10.1097\/qai.0b013e3182a23e9a","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T12:24:55Z","timestamp":1373545495000},"page":"261-270","source":"Crossref","is-referenced-by-count":6,"title":["Temporal Association Between Incident Tuberculosis and Poor Virological Outcomes in a South African Antiretroviral Treatment Service"],"prefix":"10.1097","volume":"64","author":[{"given":"Ankur","family":"Gupta-Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Lawn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-6-20210131","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/QAD.0b013e328013f632","article-title":". Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.","volume":"21","author":"Moore","year":"2007","journal-title":"AIDS"},{"key":"R3-6-20210131","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/01.aids.0000238406.93249.cd","article-title":". Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.","volume":"20","author":"Lawn","year":"2006","journal-title":"AIDS"},{"key":"R4-6-20210131","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/QAD.0b013e3283565dd1","article-title":". Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.","volume":"26","author":"Lawn","year":"2012","journal-title":"AIDS"},{"key":"R6-6-20210131","doi-asserted-by":"crossref","first-page":"e1000391","DOI":"10.1371\/journal.pmed.1000391","article-title":". Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies.","volume":"8","author":"Getahun","year":"2011","journal-title":"PLoS Med"},{"key":"R7-6-20210131","first-page":"1906","article-title":"Corbett EL, et al..","volume":"375","author":"Harries","year":"2010","journal-title":"The HIV-associated tuberculosis epidemicwhen will we act Lancet"},{"issue":"suppl 4","key":"R8-6-20210131","doi-asserted-by":"crossref","first-page":"S1159","DOI":"10.1093\/infdis\/jir411","article-title":"Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis.","volume":"204","author":"Lawn","year":"2011","journal-title":"J Infect Dis"},{"key":"R9-6-20210131","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/QAI.0b013e3181f9fb39","article-title":"Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.","volume":"56","author":"Van Rie","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-6-20210131","doi-asserted-by":"crossref","first-page":"e34156","DOI":"10.1371\/journal.pone.0034156","article-title":". Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.","volume":"7","author":"Gupta","year":"2012","journal-title":"PLoS One"},{"key":"R11-6-20210131","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1097\/QAD.0b013e32833a2507","article-title":". Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa.","volume":"24","author":"Komati","year":"2010","journal-title":"AIDS"},{"key":"R12-6-20210131","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32833a097b","article-title":". Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.","volume":"24","author":"El-Khatib","year":"2010","journal-title":"AIDS"},{"key":"R13-6-20210131","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2334-9-81","article-title":". Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.","volume":"9","author":"Ahoua","year":"2009","journal-title":"BMC Infect Dis"},{"key":"R14-6-20210131","doi-asserted-by":"crossref","first-page":"e55824","DOI":"10.1371\/journal.pone.0055824","article-title":". Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa.","volume":"8","author":"Gupta","year":"2013","journal-title":"PLoS One"},{"key":"R15-6-20210131","first-page":"315","article-title":". Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa.","volume":"96","author":"Bekker","year":"2006","journal-title":"S Afr Med J"},{"key":"R16-6-20210131","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1097\/01.aids.0000194802.89540.e1","article-title":". Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design.","volume":"19","author":"Lawn","year":"2005","journal-title":"AIDS"},{"key":"R17-6-20210131","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/135965350701200106","article-title":". Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.","volume":"12","author":"Orrell","year":"2007","journal-title":"Antivir Ther"},{"key":"R19-6-20210131","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1473-3099(09)70328-7","article-title":". Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review.","volume":"10","author":"Barth","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"R21-6-20210131","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-1293.2008.00650.x","article-title":". Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.","volume":"10","author":"Smith","year":"2009","journal-title":"HIV Med"},{"key":"R22-6-20210131","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/infdis\/jiq143","article-title":". Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.","volume":"203","author":"Li","year":"2011","journal-title":"J Infect Dis"},{"key":"R23-6-20210131","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1742-6405-8-42","article-title":". Incidence and risk factors of antiretroviral treatment failure in treatment-naive HIV-infected patients at Chiang Mai University Hospital, Thailand.","volume":"8","author":"Khienprasit","year":"2011","journal-title":"AIDS Res Ther"},{"key":"R24-6-20210131","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jama.293.7.817","article-title":". Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.","volume":"293","author":"Nettles","year":"2005","journal-title":"JAMA"},{"key":"R25-6-20210131","doi-asserted-by":"crossref","first-page":"e50065","DOI":"10.1371\/journal.pone.0050065","article-title":"Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load 48 copiesmL.","volume":"7","author":"Henrich","year":"2012","journal-title":"PLoS One"},{"key":"R26-6-20210131","first-page":"615","article-title":"Lipman M, et al..","volume":"16","author":"Moore","year":"2002","journal-title":"Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure AIDS"},{"key":"R27-6-20210131","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00002030-200207260-00009","article-title":". The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to 400 copiesml.","volume":"16","author":"Easterbrook","year":"2002","journal-title":"AIDS"},{"key":"R28-6-20210131","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/00002030-200208160-00008","article-title":". Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients.","volume":"16","author":"Raboud","year":"2002","journal-title":"AIDS"},{"key":"R29-6-20210131","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/infdis\/jis104","article-title":". Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.","volume":"205","author":"Grennan","year":"2012","journal-title":"J Infect Dis"},{"key":"R30-6-20210131","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2334-11-258","article-title":". Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South African township.","volume":"11","author":"Lawn","year":"2011","journal-title":"BMC Infect Dis"},{"key":"R31-6-20210131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAI.0b013e3182199ee9","article-title":"Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa.","volume":"57","author":"Lawn","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R32-6-20210131","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":". Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.","volume":"41","author":"Lopez-Cortes","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R33-6-20210131","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":". Efavirenz 600 mgday versus efavirenz 800 mgday in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.","volume":"20","author":"Manosuthi","year":"2006","journal-title":"AIDS"},{"issue":"suppl 1","key":"R34-6-20210131","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1086\/518655","article-title":". Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.","volume":"196","author":"McIlleron","year":"2007","journal-title":"J Infect Dis"},{"key":"R35-6-20210131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/rmv.369","article-title":". The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages.","volume":"13","author":"Kedzierska","year":"2003","journal-title":"Rev Med Virol"},{"key":"R36-6-20210131","doi-asserted-by":"crossref","first-page":"e1002464","DOI":"10.1371\/journal.ppat.1002464","article-title":". Tuberculosis and HIV co-infection.","volume":"8","author":"Pawlowski","year":"2012","journal-title":"PLoS Pathog"},{"key":"R37-6-20210131","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":". Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"key":"R38-6-20210131","doi-asserted-by":"crossref","first-page":"e1001236","DOI":"10.1371\/journal.pmed.1001236","article-title":". Nevirapine- versus lopinavirritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.","volume":"9","author":"Lockman","year":"2012","journal-title":"PLoS Med"},{"key":"R39-6-20210131","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QAI.0b013e31824e5256","article-title":"Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.","volume":"60","author":"Amoroso","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R40-6-20210131","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/cir447","article-title":". Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.","volume":"53","author":"Swaminathan","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R41-6-20210131","doi-asserted-by":"crossref","first-page":"e22778","DOI":"10.1371\/journal.pone.0022778","article-title":". Pregnancy and virologic response to antiretroviral therapy in South Africa.","volume":"6","author":"Westreich","year":"2011","journal-title":"PLoS One"},{"key":"R42-6-20210131","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","article-title":". 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.","volume":"377","author":"Samandari","year":"2011","journal-title":"Lancet"},{"key":"R43-6-20210131","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/QAD.0b013e328216f441","article-title":"The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.","volume":"21","author":"Golub","year":"2007","journal-title":"AIDS"},{"issue":"suppl 1","key":"R44-6-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3156.2010.02508.x","article-title":"Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.","volume":"15","author":"Fox","year":"2010","journal-title":"Trop Med Int Health"},{"key":"R45-6-20210131","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/507095","article-title":". Determinants of mortality and nondeath losses from an antiretroviral service in South Africa: implications for program evaluation.","volume":"43","author":"Lawn","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e3182a23e9a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T02:31:44Z","timestamp":1688351504000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201311010-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3182a23e9a","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11,1]]}}}